More on DWTX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-107.0% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/19/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Dogwood Therapeutics (NQ:DWTX)
Delayed: 1.55 +0.02 (1.31%)
Prev. Close $1.53  
Open$1.53 
52 Wk High$ 
52 Wk Low$ 
Day High$1.57 
Day Low$1.49 
P/E N/A  
EPS$ 
Volume36,567 

Friends, Peers and Foes (?): VIRI LSI (more...)

Jul 20, 2026 08:30 AM Dogwood Therapeutics enrolls 200 patients in Halneuron pain trial
Jul 20, 2026 08:30 AM Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
Jun 30, 2026 08:45 AM Dogwood Therapeutics names Iain Dukes to lead new advisory board
Jun 30, 2026 08:45 AM Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Jun 17, 2026 04:55 PM Form 8-K Dogwood Therapeutics, For: Jun 16
Jun 17, 2026 01:20 PM Form 4 Dogwood Therapeutics, For: Jun 16 Filed by: De La Rosa Abel
Jun 17, 2026 01:19 PM Form 4 Dogwood Therapeutics, For: Jun 16 Filed by: Thomas John C
Jun 17, 2026 01:18 PM Form 4 Dogwood Therapeutics, For: Jun 16 Filed by: Whitley Richard James
Jun 17, 2026 01:16 PM Form 4 Dogwood Therapeutics, For: Jun 16 Filed by: Keefer David R
May 18, 2026 08:45 AM Dogwood Therapeutics begins 12-week extension study for pain drug
View All Articles

Entities mentioned with DWTX

View All Entities